Please use a PC Browser to access Register-Tadawul
Get It
Stock Ratings | Roth MKM: Maintains a "Buy" rating on CervoMed Inc. (CRVO), raises price target from $7 to $15, with a 535.59% upside potential.
CervoMed Inc. - Common Stock +10.25% Post
Trevi Therapeutics +0.85% Post
Inuvo, Inc. -0.55% Post
Inozyme Pharma +3.65% Post
Abbott Laboratories +3.74% Post
CervoMed Inc. - Common Stock CRVO | 8.50 8.53 | +10.25% +0.35% Post |
Trevi Therapeutics TRVI | 6.53 6.53 | +0.85% 0.00% Post |
Inuvo, Inc. INUV | 0.40 0.39 | -0.55% -1.26% Post |
Inozyme Pharma INZY | 0.99 0.99 | +3.65% 0.00% Post |
Abbott Laboratories ABT | 131.35 131.90 | +3.74% +0.42% Post |
Major US investment bank ratings are used to track the latest valuations and target prices on Wall Street daily, and to explore potential stock investment opportunities.
Today's Key Ratings and Concerns
Roth MKM: Maintains a "Buy" rating on CervoMed Inc. ( CervoMed Inc. - Common Stock(CRVO.US) ), raising the price target from $7 to $15.
Oppenheimer: Maintained Trevi Therapeutics Trevi Therapeutics(TRVI.US) ) rating at “Outperform,” raising the price target from $12 to $20.
HC Wainwright & Co.: Maintained a "Buy" rating on Trevi Therapeutics ( Trevi Therapeutics(TRVI.US) ), raising the price target from $7.5 to $12.5.
HC Wainwright & Co.: Initial rating for Inuvo ( Inuvo, Inc.(INUV.US) ) with a "Buy" recommendation and a $2 price target.
Piper Sandler: Maintained Inozyme Pharma(INZY.US) ) rating at "Overweight", lowered price target from $30 to $23.
| Investment objective | The symbol | Classification | Target price | Current price | Potential increase/decrease rate | (Classification) Agency |
| CervoMed Inc. - Common Stock | CervoMed Inc. - Common Stock(CRVO.US) | to lift | $15.0 | $2.36 | 535.59% | Roth MKM |
| Trevi Therapeutics | Trevi Therapeutics(TRVI.US) | to lift | $20.0 | $6.3 | 217.46% | Oppenheimer |
| Trevi Therapeutics | Trevi Therapeutics(TRVI.US) | to lift | $12.5 | $6.3 | 98.41% | HC Wainwright & Co. |
| Myomo, Inc. | Myomo, Inc.(MYO.US) | to lift | $11.0 | $5.87 | 87.39% | Craig-Hallum |
| NET Power Inc. Class A Common Stock | NET Power Inc. Class A Common Stock(NPWR.US) | to lift | $6.0 | $3.22 | 86.34% | Citigroup |
| Inuvo, Inc. | Inuvo, Inc.(INUV.US) | Initial classification | $2.0 | $0.3623 | 452.03% | HC Wainwright & Co. |
| Inozyme Pharma | Inozyme Pharma(INZY.US) | cut | $23.0 | $1.06 | 2069.81% | Piper Sandler |
| Inozyme Pharma | Inozyme Pharma(INZY.US) | cut | $15.0 | $1.06 | 1315.09% | Needham |
| 4D Molecular Therapeutics, Inc. | 4D Molecular Therapeutics, Inc.(FDMT.US) | cut | $40.0 | $4.11 | 873.24% | B of A Securities |
| TENAYA THERAPEUTICS, INC. | TENAYA THERAPEUTICS, INC.(TNYA.US) | cut | $5.0 | $0.54 | 825.93% | HC Wainwright & Co. |
comments:
Target price unit and current price: US dollar;
Current Price: As of the latest closing price of US stocks;
Potential increase/decrease ratio = (Agency target price - current price) / current price 100% (Current price = last closing price up to the time of census)
Lifting
B of A Securities: Maintained a "Buy" rating on Abbott Laboratories(ABT.US) ), raising the price target from $133 to $150.
Evercore ISI Group: Maintained Albertsons Companies, Inc.(ACI.US) s "Market Match" rating, raising the price target from $21 to $22.
JP Morgan: Maintained a "Neutral" rating on Alnylam Pharmaceuticals Alnylam Pharmaceuticals, Inc(ALNY.US) ), raising the price target from $272 to $280.
Citigroup: Maintained a "buy" rating on American Tower American Tower Corporation(AMT.US) ), raising the price target from $220 to $235.
First coverage
RBC Capital: Initial rating for Aardvark Therapeutics ( Aardvark Therapeutics, Inc.(AARD.US) ) with an "Outperform" recommendation and a $21 price target.
Needham: Initial rating for Backblaze ( BACKBLAZE, INC.(BLZE.US) ) with a "Buy" recommendation and a $8 price target.
TD Securities: Initial rating for Coeur Mining, Inc.(CDE.US) ) with a "Buy" recommendation and a $7 price target.
reduction
Evercore ISI Group: Maintained Advance Auto Parts ( Advance Auto Parts, Inc.(AAP.US) "Market Match" rating, lowered price target to $35 from $37.
Citigroup: Maintained a "Neutral" rating on Adobe ( Adobe Systems Incorporated(ADBE.US) ), lowering the price target from $551 to $490.
Canaccord Genuity: Maintained a "Buy" rating on Advantage Solutions ( Advantage Solutions Inc. - Class A Common Stock(ADV.US) ), while lowering the price target from $5.5 to $3.5.
Editor's Note: This content was generated by Sahm's AI-powered SaaS tool and reviewed by our editorial team.
Hazard Warning:
Investing involves risks, and securities prices may rise, fall, or even become worthless. Investing does not guarantee profits and may result in losses. Past performance does not necessarily reflect future performance. Before making any investment decision, investors should evaluate their financial situation, investment objectives, experience, and risk tolerance, and understand the nature of the investment products and the risks associated with them. For further details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, you are advised to seek independent professional advice.
